Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Urinary Tract Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Urinary Tract Infections - Pipeline Review, H1 2015', provides an overview of the Urinary Tract Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Urinary Tract Infections Overview 10 Therapeutics Development 11 Pipeline Products for Urinary Tract Infections - Overview 11 Pipeline Products for Urinary Tract Infections - Comparative Analysis 12 Urinary Tract Infections - Therapeutics under Development by Companies 13 Urinary Tract Infections - Therapeutics under Investigation by Universities/Institutes 16 Urinary Tract Infections - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Urinary Tract Infections - Products under Development by Companies 20 Urinary Tract Infections - Products under Investigation by Universities/Institutes 23 Urinary Tract Infections - Companies Involved in Therapeutics Development 24 Achaogen Inc. 24 Adenium Biotech ApS 25 AstraZeneca PLC 26 ConjuGon, Inc. 27 Cubist Pharmaceuticals, Inc. 28 Da Volterra 29 DexTech Medical AB 30 FOB Synthesis, Inc. 31 GlycoVaxyn AG 32 Melinta Therapeutics, Inc 33 Merck & Co., Inc. 34 MerLion Pharmaceuticals Pte Ltd 35 Nabriva Therapeutics AG 36 NovaBay Pharmaceuticals, Inc. 37 Nymox Pharmaceutical Corporation 38 Osel Inc. 39 Paratek Pharmaceuticals, Inc. 40 Sequoia Sciences, Inc. 41 Shionogi & Co., Ltd. 42 Syntiron LLC 43 Tetraphase Pharmaceuticals Inc. 44 The Medicines Company 45 Urinary Tract Infections - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (ceftaroline fosamil + avibactam sodium) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 (ceftazidime + avibactam sodium) - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 (ceftolozane sulfate + tazobactam sodium) - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 (meropenem+ RPX-7009) - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 AA-139 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 auriclosene - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 C-1205 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 CatDex - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 cefepime - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 DAV-210 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 delafloxacin - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Drugs to Inhibit COX-2 for Urinary Tract Infections - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 EBX-002 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 eravacycline - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Escherichia coli vaccine - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 extraintestinal pathogenic escherichia coli vaccine - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 finafloxacin - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 FSI-1686 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 GP-4 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 klebsiella pneumoniae vaccine - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 LACTIN-V - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Micselon - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Nu-2 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Nu-3 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 NXB-4221 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 omadacycline - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 plazomicin sulfate - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Proteins for Infectious Diseases - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 relebactam - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 S-649266 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Vaccine for Urinary Tract Infection - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 ZTI-01 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Urinary Tract Infections - Recent Pipeline Updates 102 Urinary Tract Infections - Dormant Projects 125 Urinary Tract Infections - Discontinued Products 127 Urinary Tract Infections - Product Development Milestones 128 Featured News & Press Releases 128 Jan 08, 2015: MerLion's Finafloxacin Shows Positive Phase 2 Results in Complicated Urinary Tract Infections 128 Dec 19, 2014: FDA approves new antibacterial drug Zerbaxa 129 Dec 05, 2014: Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 129 Oct 08, 2014: Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria 130 Oct 06, 2014: Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI 131 Sep 04, 2014: Merck's Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA 132 Sep 02, 2014: Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion 132 Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 133 Jul 01, 2014: GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection 134 Jun 19, 2014: Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review 135 Appendix 136 Methodology 136 Coverage 136 Secondary Research 136 Primary Research 136 Expert Panel Validation 136 Contact Us 136 Disclaimer 137
List of Tables Number of Products under Development for Urinary Tract Infections, H1 2015 11 Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Products under Development by Companies, H1 2015 20 Products under Development by Companies, H1 2015 (Contd..1) 21 Products under Development by Companies, H1 2015 (Contd..2) 22 Products under Investigation by Universities/Institutes, H1 2015 23 Urinary Tract Infections - Pipeline by Achaogen Inc., H1 2015 24 Urinary Tract Infections - Pipeline by Adenium Biotech ApS, H1 2015 25 Urinary Tract Infections - Pipeline by AstraZeneca PLC, H1 2015 26 Urinary Tract Infections - Pipeline by ConjuGon, Inc., H1 2015 27 Urinary Tract Infections - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 28 Urinary Tract Infections - Pipeline by Da Volterra, H1 2015 29 Urinary Tract Infections - Pipeline by DexTech Medical AB, H1 2015 30 Urinary Tract Infections - Pipeline by FOB Synthesis, Inc., H1 2015 31 Urinary Tract Infections - Pipeline by GlycoVaxyn AG, H1 2015 32 Urinary Tract Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 33 Urinary Tract Infections - Pipeline by Merck & Co., Inc., H1 2015 34 Urinary Tract Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2015 35 Urinary Tract Infections - Pipeline by Nabriva Therapeutics AG, H1 2015 36 Urinary Tract Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 37 Urinary Tract Infections - Pipeline by Nymox Pharmaceutical Corporation, H1 2015 38 Urinary Tract Infections - Pipeline by Osel Inc., H1 2015 39 Urinary Tract Infections - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 40 Urinary Tract Infections - Pipeline by Sequoia Sciences, Inc., H1 2015 41 Urinary Tract Infections - Pipeline by Shionogi & Co., Ltd., H1 2015 42 Urinary Tract Infections - Pipeline by Syntiron LLC, H1 2015 43 Urinary Tract Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 44 Urinary Tract Infections - Pipeline by The Medicines Company, H1 2015 45 Assessment by Monotherapy Products, H1 2015 46 Assessment by Combination Products, H1 2015 47 Number of Products by Stage and Target, H1 2015 49 Number of Products by Stage and Mechanism of Action, H1 2015 51 Number of Products by Stage and Route of Administration, H1 2015 53 Number of Products by Stage and Molecule Type, H1 2015 55 Urinary Tract Infections Therapeutics - Recent Pipeline Updates, H1 2015 102 Urinary Tract Infections - Dormant Projects, H1 2015 125 Urinary Tract Infections - Dormant Projects (Contd..1), H1 2015 126 Urinary Tract Infections - Discontinued Products, H1 2015 127
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
